Business
HeartBeam Reports Third Quarter 2022 Financial Results
HeartBeam AIMI™ Platform Technology for use in Diagnosing Heart Attacks Submitted to FDA for Clearance Company on Track for Initial FDA Submission of
About this update from Heartbeam, Inc.
[{"type":"text","content":"\n HeartBeam AIMI™ Platform Technology for use in Diagnosing Heart Attacks Submitted to FDA for Clearance\n\nCompany on Track for Initial FDA Submission of HeartBeam AIMIGo™, the Telehealth Solution, in Q4 2022\n\nAIMIGo Technology Receives Two Additional Patents\n\nCompany Plans to Broaden Product Portfolio Pipeline with Smartwatch Connectivity\n\nManagement to Host Webcast and Conference Call Today At 4:30 p.m. ET\n\n SANTA CLARA, Calif.--(BUSINESS WIRE)--\nHeartBeam, Inc. (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector electrocardiogram (VECG) platform for heart attack detection anytime, anywhere, has reported its financial and operational results for the third quarter ended September 30, 2022.\n\nThird Quarter and Subsequent 2022 Operational Highlights\n\n\nAnnounced the US Food and Drug Administration (FDA) 510(k) application submission of HeartBeam AIMI platform, seeking approval for the Company’s proprietary VECG technology to aid in diagnosis of heart attack in $500 million total addressable market\n\n\nBroadened product portfolio pipeline with smartwatch connectivity supporting a daily multi-hour heart monitoring solution, leveraging the HeartBeam AIMIGo platform to address the multibillion-dollar global market for detection of atrial arrhythmias\n\n\nGranted patent for signal transformation from VECG to 12-Lead Electrocardiogram (ECG), allowing the HeartBeam AIMIGo credit card-sized device to enable a 12-lead ECG anytime, anywhere\n\n\nGranted patent for 12-lead ECG patch monitor intended for detection of heart attacks and complex cardiac arrhythmias, opening a pathway to a disruptive ischemia and arrhythmia detection via 12-lead ECG patch product\n\n\nExpanded the addressable patient population for the Company’s HeartBeam AIMI software platform to provide access to a broader patient population in the emergency care setting\n\n\nAppointed Peter J. Fitzgerald, MD, PhD, as Chief Medical Officer, a renowned Stanford cardiologist who brings deep clinical, research, and industry expertise to the executive team\n\n\nAppointed healthcare and cardiac industry veteran, Ken Persen, to the role of Chief Technology Officer\n\n\nSelected as winner of the annual Cardiovascular Innovations (CVI) 2022 Innovation Summit and Shark Tank Competition, an annual awards program recognizing innovat...